## Beta Cell Dysfunction Progression in Type 2 Diabetes ### Natural History of Type 2 DM **Key Point:** Type 2 Diabetes is characterized by a **dual defect**: (1) insulin resistance in peripheral tissues and (2) **progressive failure of beta cells to compensate** for that resistance. ### Timeline of Beta Cell Dysfunction ```mermaid flowchart TD A["Insulin Resistance Develops"]:::outcome --> B["Beta Cells Hyperfunction<br/>Hyperinsulinemia"]:::action B --> C["Glucose Tolerance Maintained<br/>IGT/IFG Stage"]:::outcome C --> D["Progressive Beta Cell Exhaustion"]:::urgent D --> E["Declining Insulin Secretion"]:::urgent E --> F["Overt Hyperglycemia<br/>Type 2 DM Diagnosed"]:::outcome F --> G["Further Beta Cell Loss<br/>Eventual Insulin Dependence"]:::urgent ``` ### Key Phases 1. **Pre-diabetes phase**: Insulin resistance present, but beta cells compensate with increased insulin secretion → normal glucose tolerance 2. **Impaired glucose tolerance (IGT) / Impaired fasting glucose (IFG)**: Insulin resistance worsens, beta cell compensation begins to fail → mild hyperglycemia 3. **Overt Type 2 DM**: Progressive decline in beta cell function despite ongoing insulin resistance → frank hyperglycemia 4. **Late-stage Type 2 DM**: Severe beta cell failure; some patients require insulin therapy ("Type 2 DM on insulin") **High-Yield:** At the time of Type 2 DM diagnosis, approximately **50% of beta cell function has already been lost**. By 10 years, this may decline to 25–30% of original capacity. **Clinical Pearl:** The **Disposition Index** (product of insulin sensitivity and beta cell function) is a useful marker: it declines progressively in Type 2 DM, explaining why glucose control worsens over time despite treatment. **Mnemonic: RISE** — **R**esistance, **I**ncreased insulin output, **S**econdary failure, **E**ventual insulin dependence (in some Type 2 patients).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.